Literature DB >> 27566060

Expression and purification of recombinant TAT-BoNT/A(1-448) under denaturing and native conditions.

Parvaneh Saffarian1, Shahin Najar Peerayeh2, Jafar Amani3, Firooz Ebrahimi4, Hamid Sedighianrad4, Raheleh Halabian4, Abbas Ali Imani Fooladi4.   

Abstract

Botulinum toxin type A can temporarily inhibit muscle contraction. Currently, physicians administer this toxin as a bio-drug in treatment of some muscle contraction disorders. TAT-BoNT/A(1-448) is a functional recombinant protein derived from botulinum toxin light chain. Unlike the full length botulinum toxin, TAT-BoNT/A(1-448) is a self-permeable molecule which can pass through bio-surfaces so can be used as a topical therapeutic agent without injection. To maintain the functionality of TAT-BoNT/A(1-448), it is necessary to restore its normal folding upon expression and purification. In this study, we have investigated and optimized expression conditions for this novel recombinant protein. Under denaturing condition (1 mM IPTG, at 37°C), the chimeric protein was produced as inclusion body and required to be purified using denaturing agents (e.g. urea). Yet, lower incubation temperature (18°C) and less IPTG concentration (0.5 mM) induce a protein under native condition. In such condition, about 60% of the chimeric protein was expressed in soluble form.

Entities:  

Keywords:  TAT-BoNT/A(1–448); cell-penetrating peptide; inclusion body; light chain of botulinum toxin type A; protein expression

Mesh:

Substances:

Year:  2016        PMID: 27566060      PMCID: PMC5241812          DOI: 10.1080/21655979.2016.1201252

Source DB:  PubMed          Journal:  Bioengineered        ISSN: 2165-5979            Impact factor:   3.269


  21 in total

1.  Expression, purification and transduction of PEP-1-botulinum neurotoxin type A (PEP-1-BoNT/A) into skin.

Authors:  Dae Won Kim; So Young Kim; Jae Jin An; Sun Hwa Lee; Sang Ho Jang; Moo Ho Won; Tae Cheon Kang; Kwang-Hoe Chung; Hyun-Ho Jung; Sung-Woo Cho; Jin Hi Choi; Jinseu Park; Won Sik Eum; Soo Young Choi
Journal:  J Biochem Mol Biol       Date:  2006-09-30

2.  Botulinum toxin in headache treatment: the end of the road?

Authors:  Alexander Mauskop
Journal:  Cephalalgia       Date:  2007-05       Impact factor: 6.292

3.  Comparison of cellular uptake using 22 CPPs in 4 different cell lines.

Authors:  Judith Mueller; Ines Kretzschmar; Rudolf Volkmer; Prisca Boisguerin
Journal:  Bioconjug Chem       Date:  2008-12       Impact factor: 4.774

4.  Crystal structure of botulinum neurotoxin type A and implications for toxicity.

Authors:  D B Lacy; W Tepp; A C Cohen; B R DasGupta; R C Stevens
Journal:  Nat Struct Biol       Date:  1998-10

5.  Sequence homology and structural analysis of the clostridial neurotoxins.

Authors:  D B Lacy; R C Stevens
Journal:  J Mol Biol       Date:  1999-09-03       Impact factor: 5.469

6.  Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.

Authors:  Nizamettin Gul; Leonard A Smith; S Ashraf Ahmed
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

Review 7.  The use of botulinum toxin in the treatment of headaches.

Authors:  Alexander Mauskop
Journal:  Curr Pain Headache Rep       Date:  2002-08

8.  High level expression of the light chain of botulinum neurotoxin serotype C1 and an efficient HPLC assay to monitor its proteolytic activity.

Authors:  Richa Rawat; S Ashraf Ahmed; Subramanyam Swaminathan
Journal:  Protein Expr Purif       Date:  2008-03-25       Impact factor: 1.650

9.  Papillary thyroid carcinoma in a 4-year-old boy.

Authors:  Jamin A Contractor; Farida Wadia; Alpesh Patel; Manish Bamania; Vineel Muppidi
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2002-04

10.  Botulinum neurotoxins are zinc proteins.

Authors:  G Schiavo; O Rossetto; A Santucci; B R DasGupta; C Montecucco
Journal:  J Biol Chem       Date:  1992-11-25       Impact factor: 5.157

View more
  3 in total

1.  Novel Native and Engineered Botulinum Neurotoxins.

Authors:  Lance Steward; Mitchell F Brin; Amy Brideau-Andersen
Journal:  Handb Exp Pharmacol       Date:  2021

Review 2.  The Expanding Therapeutic Utility of Botulinum Neurotoxins.

Authors:  Elena Fonfria; Jacquie Maignel; Stephane Lezmi; Vincent Martin; Andrew Splevins; Saif Shubber; Mikhail Kalinichev; Keith Foster; Philippe Picaut; Johannes Krupp
Journal:  Toxins (Basel)       Date:  2018-05-18       Impact factor: 4.546

3.  Expression and Purification of Extracellular Solute-Binding Protein (ESBP) in Escherichia coli, the Extracellular Protein Derived from Bifidobacterium longum KACC 91563.

Authors:  Minyu Song; Hyaekang Kim; Woori Kwak; Won Seo Park; Jayeon Yoo; Han Byul Kang; Jin-Hyoung Kim; Sun-Moon Kang; Hoa Van Ba; Bu-Min Kim; Mi-Hwa Oh; Heebal Kim; Ham Jun-Sang
Journal:  Food Sci Anim Resour       Date:  2019-08-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.